Many of the drugs commonly used in palliative care are not listed on the Pharmaceutical Benefits Scheme in Australia and are therefore not freely available to patients outside the acute hospital system. In an attempt to address the inequity faced by patients being cared for in the community or hospices, the Palliative Care Medicines Working Group was established by the Australian Government. This has resulted in a separate palliative section within the Schedule of Pharmaceutical Benefits Scheme which allows for authority prescribing of a number of medications that may be required by a palliative care patient. This paper discusses the medications currently on this listing, the processes by which they were selected and the ongoing efforts to ...
Abstract Background While the home is the most common setting for the provision of palliative care i...
Context Dying patients commonly experience potentially distressing symptoms. Palliative care guidel...
Background: Regulatory bodies including the European Medicines Agency register medications (formulat...
surveyed to compile a list of the medications they considered essential in the practice of palliativ...
BACKGROUND: There is a disparity of availability and cost of drugs in the community for palliative c...
Introduction: To provide an overview of drug use in palliative care worldwide and to identify the mo...
Key words: drug utilisation; prescriptions, drug; palliative treatment The objective was to compile ...
Timely access to medicines within the community is important for palliative patients where their pre...
Timely access to medicines within the community is important for palliative patients where their pre...
The proposal by Lindqvist and colleagues of four essential medicines for the control of terminal sy...
textabstractBackground In end-of-life care, symptoms of discomfort are mainly managed by drug therap...
Many palliative care patients wish to remain at home for as long a possible. To help achieve this a...
Abstract Background In end-of-life care, symptoms of discomfort are mainly managed by drug therapy, ...
North West Tasmania is a vast and remote region with an ageing population. Since elderly people are ...
Background:Patient and carer access to medicines during the last 12 months of life (end-of-life) is ...
Abstract Background While the home is the most common setting for the provision of palliative care i...
Context Dying patients commonly experience potentially distressing symptoms. Palliative care guidel...
Background: Regulatory bodies including the European Medicines Agency register medications (formulat...
surveyed to compile a list of the medications they considered essential in the practice of palliativ...
BACKGROUND: There is a disparity of availability and cost of drugs in the community for palliative c...
Introduction: To provide an overview of drug use in palliative care worldwide and to identify the mo...
Key words: drug utilisation; prescriptions, drug; palliative treatment The objective was to compile ...
Timely access to medicines within the community is important for palliative patients where their pre...
Timely access to medicines within the community is important for palliative patients where their pre...
The proposal by Lindqvist and colleagues of four essential medicines for the control of terminal sy...
textabstractBackground In end-of-life care, symptoms of discomfort are mainly managed by drug therap...
Many palliative care patients wish to remain at home for as long a possible. To help achieve this a...
Abstract Background In end-of-life care, symptoms of discomfort are mainly managed by drug therapy, ...
North West Tasmania is a vast and remote region with an ageing population. Since elderly people are ...
Background:Patient and carer access to medicines during the last 12 months of life (end-of-life) is ...
Abstract Background While the home is the most common setting for the provision of palliative care i...
Context Dying patients commonly experience potentially distressing symptoms. Palliative care guidel...
Background: Regulatory bodies including the European Medicines Agency register medications (formulat...